Mithra Announces 2021 Financial Calendar

Liege, Belgium, 12 January 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces its financial calendar for 2021 :

  • 9 March 2021 : 2020 Full Year Results
  • 20 April 2021 : 2020 Annual Report
  • 20 May 2021 : Annual General Shareholders Meeting
  • 24 September 2021 : 2021 Interim report

This calendar and all corporate information on the Company (financial statements, events or corporate presentations) is available on the Company’s website in the Investors’ section  (investors.mithra.com).

Richter and Mithra strengthen their partnership and signed a license and supply agreement for the commercialization of Estelle® to Latin America

Budapest, Hungary – Liege, Belgium – 23 December 2020 – 7:30 CET –Gedeon Richter Plc. (‘Richter’) and Estetra S.A, the wholly owned subsidiary of Mithra (Euronext Brussels: MITRA), today announced that they have extended their partnership and signed a license and supply agreement for the commercialization of Estelle®, a novel 15 mg estetrol (E4) / 3 mg drospirenone containing combined oral contraceptive, in order to include key markets in Latin America. The product candidate is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues combined with additional benefits of drospirenone.

Mithra Announces Positive DSMB Safety Review and Continuation of its Phase III Clinical Program Donesta® in menopause

  • Independent Data Safety Monitoring Board (DSMB) confirms the acceptable safety profile of Donesta® and recommends to continue the Phase III Clinical Program as planned
  • On track to target marketing authorization in 2023
  • Consolidation of business development strategy of Donesta® by successful major funding transactions in 2020

Liege, Belgium, 16 December 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that its independent Data and Safety Monitoring Board (DSMB) completed its end-of-year safety assessment of the Phase III Clinical Program of Donesta®, a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).

Mithra announces final terms of its offering of EUR 125 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 20:30 CET – With reference to the two press releases issued on 10 December 2020 at 08:00 and 17:30 CET respectively, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces the final terms of the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”).

Mithra announces placement of EUR 125 million convertible bonds due 2025

  • Placement of EUR 125 million senior unsecured convertible bonds due 17 December 2025 has been completed;
  • The Bonds will bear a coupon of 4.250% per annum;
  • The initial conversion price will be set at a 25.00% premium above the reference price, which will be equal to the volume weighted average price of an ordinary share of Mithra on Euronext Brussels from market open to the close of trading on 10 December 2020 and will be announced by press release after the close of trading on Euronext Brussels today.

Liege, Belgium, 10 December 2020 – 17:30  CET – With reference to the press release issued on 10 December 2020 at 08:00 CET, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces that the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”) has been completed.

Mithra launches an offering of up to EUR 150 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 08:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today the launch of an offering (the “Offering”) of senior unsecured convertible bonds due 17 December 2025 (the “Bonds”), for an initial aggregate principal amount of EUR 125 million with an increase option of up to EUR 25 million to be exercised at the discretion of the Company before pricing.

Scientific community convinced of Estetrol’s potential for women’s health

  • At the 19th ISGE Congress, Mithra and Gedeon Richter presented the clinical results of Estelle® to an international scientific audience
  • While Estetrol (E4) has recently been designated as a “New Active Substance” by the European Medicines Agency (EMA), doctors there have confirmed their strong interest in the use of E4 in contraception.

Liege, Belgium, 3 December, 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that physicians at the 19th Congress of the International Society of Gynecologic Endocrinology (ISGE) expressed a strong interest in the clinical results of Estelle®, Mithra’s novel combined oral contraceptive (COC) candidate.

Read the press release

Mithra’s exclusivity on Estetrol applications extended to 2036 in Europe

Thanks to a new patent relating to Estetrol applications, Mithra secures its future results. A similar process is underway for the US market.

Liège, Belgique, 30 novembre 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted a new patent by the European Patent Office (EPO) relating to various pharmaceutical compositions containing Estetrol (E4) and their manufacturing process. In doing so, Mithra consolidates its exclusivity for the use of E4 in a wide range of indications such as the treatment of hormone-dependent cancers (breast and prostate in particular), dermatology, neuroprotection, dysmenorrhea and emergency contraception

 

Estetrol recognized as a “New Active Substance” by the European Medicines Agency (EMA)

This is the first time in more than 80 years that a new estrogen has been introduced in the field of contraception.

Liège, Belgium, 25 November 2020 – 7:30 CET – Mithra, a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that the European Medicines Agency (EMA) has designated Estetrol monohydrate (E4) as a New Active Substance (NAS) in its “Day 180” report, concluding the second phase of the ongoing evaluation of Estelle® birth control pills for the European market.

Creation of a New Share Option Plan in Replacement of the 2018 Share Option Plan

Liege, Belgium, 20 November 2020 – 17:45 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that its board of directors has issued, within the framework of the authorized capital, a new share option plan for its personnel, covering 390,717 share options (the “2020 Share Option Plan”).